30th Jan 2009 07:03
30 January 2009
HENDERSON MORLEY PLC
(AIM: HML)
("Henderson Morley" or "the Company")
Eel Herpes vaccine partnership
The Board of Henderson Morley Plc, the AIM quoted biotechnology company, is pleased to announce a co-development agreement with UK Glass Eels Ltd, ("UK Glass Eels") to produce a vaccine against Eel Herpes.
Under this agreement, a vaccine will be supplied to UK Glass Eels on a commercial basis, and UK Glass Eels will have non exclusive rights to distribute the vaccine on a worldwide basis.
The vaccine is already in advanced stages of development. It will be administered to eels whilst at the glass eel phase of their life-cycle. It is expected that first revenues from this partnership will be received during 2009.
Eel farming in the EU has suffered considerable stock losses due to a recently identified virus, Herpes Virus Anguilarum (Eel herpes virus). UK Glass Eels is one of Europe's largest suppliers of glass eels for the re-stocking of eel farms, supplying almost one third of the EU market.
The co-development is as a direct result of Henderson Morley's expertise regarding other herpes virus infections in fish, as much of the technology and expertise applied in the other projects is applicable to the development of this vaccine.
Proprietor of UK Glass Eels, Peter Wood FRCVS stated "We are very pleased to be collaborating on this project. The impact that Eel herpes virus has been making on the eel farming community is significant, with many farmers suffering considerable financial losses as a consequence. An effective vaccine for the prevention of this infection could offer a significant commercial benefit to the eel industry."
Chairman Andrew Knight commented "UK Glass Eels is the European leader in the supply of fish to the eel farming industry. We are very pleased to be partners in this co-development especially as we expect it to be revenue generating in 2009."
---ENDS---
ENQUIRIES:
HENDERSON MORLEY PLC 0121 442 4600
Andrew Knight, Chairman
BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350 (Public Relations) Maxine Barnes Nick Rome
BREWIN DOLPHIN INVESTMENT BANKING 0113 241 0126
(Nominated Adviser)
Neil Baldwin
HYBRIDAN LLP 0203 159 5085
(Broker)
Claire Noyce/Stephen Austin
Notes to Editors:
Henderson Morley was founded in 1996 with the objective of developing its anti viral application (Ionic Contra Viral Therapy (ICVT). ICVT is the Lead Platform and has been developed in-house and HML wholly owns the patent IPR.
Further information on Henderson Morley plc can be accessed through the Company's website at www.henderson-morley.com
Related Shares:
HML.L